SAMSUNG BIOLOGICS CO LTD

Samsung Biologics offers a 40% premium to acquire PolyPeptide, boosting its global peptide‑manufacturing footprint and accelerating life‑science growth.

Samsung Biologics’ all‑cash tender offer for PolyPeptide Group AG boosts its peptide‑API expertise, expanding global CDMO services and growth prospects.